TD Cowen raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $99 from $59 and keeps a Buy rating on the shares. The firm updated its model following solid Q3 results driven by Tryngolza beat/raise. Cowen is adding $1.5B in peak global sales to theirmodel at $25k/yr.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Future Catalysts Support Buy Rating
- Ionis Pharmaceuticals price target raised to $95 from $80 at Barclays
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating
- Ionis Pharmaceuticals Reports Strong Q3 2025 Growth
- Ionis Pharmaceuticals Shines in Q3 2025 Earnings Call